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B cell receptor (BCR) signaling plays a critical
role in B cell tolerance and activation. Here, we
show that mice with B cell-specific ablation of
both Cbl and Cbl-b (Cbl/Cblb/) manifested
systemic lupus erythematosus (SLE)-like auto-
immune disease. The Cbl double deficiency re-
sulted in a substantial increase in marginal
zone (MZ) and B1 B cells. The mutant B cells
were not hyperresponsive in terms of prolifera-
tion and antibody production upon BCR stimu-
lation; however, B cell anergy to protein antigen
appeared to be impaired. Concomitantly, BCR-
proximal signaling, including tyrosine phos-
phorylation of Syk tyrosine kinase, Phospholi-
pase C-g2 (PLC-g2), and Rho-family GTP-GDP
exchange factor Vav, and Ca2+ mobilization
were enhanced, whereas tyrosine phosphoryla-
tion of adaptor protein BLNK was substan-
tially attenuated in the mutant B cells. These re-
sults suggested that the loss of coordination
between these pathways was responsible for
the impaired B cell tolerance induction. Thus,
Cbl proteins control B cell-intrinsic checkpoint
of immune tolerance, possibly through coordi-
nating multiple BCR-proximal signaling path-
ways during anergy induction.
INTRODUCTION
Bcell development, activation, and tolerance are intercon-
nected processes controlled by signals delivered by the B
cell receptor (BCR) (Healy andGoodnow, 1998; Rajewsky,
1996; Reth andWienands, 1997). Paradoxically, the same
BCR can either signal immunogenically, stimulating the
proliferation and differentiation of B cells specific for for-eign antigens, or signal tolerogenically to eliminate or
silence cells that bind to self-antigens. Although divergent
hypotheses exist as to how precisely BCR signaling is trig-
gered by antigen and how this signaling is quantitatively
and differentially altered in tolerized B cells (Healy et al.,
1997; Vilen et al., 2002), the developmental timing when
B cells encounter antigens may determine the final out-
comes (Cancro, 2004;Chung et al., 2003). In particular, ev-
idence indicate that triggering of the antigen receptors on
bone-marrow (BM) immature and peripheral transitional
(T1 or T2) B cells leads to B cell tolerance in the absence
of T cell help (Allman et al., 1992; Carsetti et al., 1995;
Fulcher and Basten, 1994). These findings thus support
the idea that the immature stages of B cell development
may represent a timewindowduringwhichBcell tolerance
is established. After these stages, binding of antigens to
the BCR on mature B cells results in B cell activation.
The BCR complex is composed of antigen-binding im-
munoglobulin Ig molecules and noncovalently associated
signal-transduction molecules, Ig-a- and Ig-b-containing
cytoplasmic domain immunoreceptor tyrosine-based ac-
tivation motifs (ITAMs) (Cambier, 1995b; Campbell,
1999; Reth, 1989, 1992). Crosslinking of the BCR results
in tyrosine phosphorylation of the ITAMs by Src-family ty-
rosine kinase Lyn followed by recruitment and activation
of Syk tyrosine kinase (Cambier, 1995a; Reth and Wie-
nands, 1997). Recruitment and activation of Syk by the
phosphorylated BCR is a key event in the assembly of
the BCR signalosome composed of the adaptor protein
BLNK (B cell linker protein) and downstream signaling
components phospholipase C-g2 (PLC-g2), Bruton’s ty-
rosine kinase (Btk), and Rho-family GTP-GDP exchange
factor Vav (Kurosaki, 2002; Pierce, 2002). These compo-
nents coordinately induce Ca2+ influx and activate nu-
clear-transcription factors including NF-AT, AP-1, and
NF-kB that are essential for B cell development and acti-
vation (Campbell, 1999; Kurosaki, 2000).
Casitas B lineage lymphoma (Cbl) proteins were re-
cently identified as E3 ubiquitin ligase (Joazeiro et al.,
1999). They interact with E2-ubiquitin-conjugatingImmunity 26, 567–578, May 2007 ª2007 Elsevier Inc. 567
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Role of Cbl Ubiquitin Ligases in B Cell Toleranceenzyme (Ubc) through their RING finger (RF) domain and
regulate the signaling of a broad range of receptors by
promoting ubiquitination of the components involved in
this receptor signaling (Duan et al., 2004; Liu and Gu,
2002; Thien and Langdon, 2005). In mammals, the Cbl
family of proteins has three members, Cbl, Cbl-b, and
Cbl-3, among which Cbl and Cbl-b are expressed in he-
matopoietic cells (Duan et al., 2004). Recent genetic stud-
ies from our and several other laboratories have revealed
a critical role of Cbl proteins in T cell development and
activation (Bachmaier et al., 2000; Chiang et al., 2000;
Murphy et al., 1998; Naramura et al., 1998, 2002). The
role of Cbl in B cell development and function requires fur-
ther investigation. The involvement of Cbl proteins in BCR
signaling has been reported in several papers, in which
Cbl and Cbl-b were shown to regulate PLC-g2 activation
and Ca2+ response (Sohn et al., 2003; Yasuda et al.,
2000, 2002). Cbl proteins associate with Syk and BLNK
upon BCR stimulation, suggesting that they are part of
the BCR signalosome. Cbl-b deficiency leads to an
enhanced tyrosine phosphorylation of Syk and Ca2+ re-
sponse in mouse B cells, despite normal BCR-induced
proliferation of Cblb/ B cells (Sohn et al., 2003). How-
ever, the precise signaling and physiological function of
Cbl proteins in B cell biology has not yet been fully ad-
dressed, to some extent as a result of functional redun-
dancy between Cbl and Cbl-b.
In order to understand the biochemical and physiologi-
cal functions of Cbl proteins in B cells, we have generated
a mousemodel in which Cbl and Cbl-b are simultaneously
inactivated in B lineage cells. Our study revealed that
these mice manifested systemic lupus erythematosus
(SLE)-like disease. The mutation substantially increased
the rate of B cell maturation and impaired B cell anergy.
These results thus indicate that Cbl proteins control
a checkpoint of B cell tolerance, possibly by extending
the duration of B cell maturation, providing sufficient
time for the induction of B cell tolerance.
RESULTS
Generation of B Cell-Specific Cbl
and Cbl-b Double-Deficient Mice
Our previous data demonstrate that inactivation of the
germline Cbl or Cblb gene alone results in a negligible im-
pact on the development and function of B cells; however,
the simultaneous ablation of both Cbl and Cblb genes in
germline leads to embryonic lethality (Naramura et al.,
2002), suggesting that Cbl and Cbl-b may have a redun-
dant role in intracellular signaling. To assess whether Cbl
and Cbl-b have a redundant function in B cells, we gener-
ated mutant mice in which the Cbl and Cblb genes were
simultaneously inactivated only in B cells. These mice
carried the homozygous Cblf/f (Cbl gene flanked by loxP
sequences) alleles and Cblb/ (Cblb null) alleles and
a Cd19-cre transgene (Tg). Deletion of the Cblf/f alleles in
a given cell by the Cre recombinase resulted in ablation
of both genes, so we expected that the double deficiency568 Immunity 26, 567–578, May 2007 ª2007 Elsevier Inc.in these mice would occur only in B cells, because Cd19-
cre transgenewas expressed specifically in B lineage cells
(Rickert et al., 1997). Indeed, we found that in these mice,
theCblf/f alleles were deleted efficiently in B but not T cells
(Figures S1A–S1C in the Supplemental Data available
online). Hereafter we will refer to Cblf/fCblb/Cd19-cre
Tg mice as Cbl/Cblb/ mice.
Altered B Cell Development in Cbl/Cblb/ Mice
Cbl/Cblb/ mice were born normal and fertile and ex-
hibited no gross abnormality in major organs (data not
shown). To determine whether the Cbl/Cblb/ muta-
tion altered B cell development, we analyzed B cell com-
partments of the bonemarrow (BM), spleen, lymph nodes,
and peritoneal cavity from themutant mice by flow cytom-
etry (Figure 1A). Cbl/Cblb/ and WT control mice pos-
sessed comparable numbers of BM B (B220+) cells, as
well as similar representation of BMB cell subsets, includ-
ing pro- and pre- (B220lo IgM), immature (B220lo IgM+),
and mature recirculating (B220hi IgM+) B cells. These ob-
servations were expected because Cd19-Cre-mediated
deletion occurred in less than 40%of pro- and pre-B cells,
whereas almost complete deletion was found only in ma-
ture B cells (Figure S1D). On the contrary, we found that
the mutant mice possessed approximately 30% more B
(B220+) cells than did the WT mice and altered represen-
tations of B cell subsets in spleen and peritoneal cavity
(Figures 1A and 1C), suggesting that the Cbl/Cblb/
mutation affected peripheral B cell development. To de-
termine which subsets of peripheral B cells were affected
by theCbl/Cblb/mutation, we analyzed the cellularity
of splenic B cell subsets by flow cytometry. We found that
Cbl/Cblb/ mice possessed approximately 2-fold
more splenic T1 (B220+ AA4.1hi HSAhi CD21lo CD23lo),
B1 (B220+ AA4.1lo HSAlo CD21 CD23), and marginal
zone (MZ) (B220+ AA4.1lo HSAlo CD21hi CD23) B cells
as compared to WT mice; however, the total numbers of
follicular (FO) (B220+ AA4.1lo HSAlo CD21+ CD23+) and
T2 (B220+ AA4.1hi HSAhi CD21hi CD23hi) B cells were com-
parable between the mutant andWTmice (Figures 1B and
1C). Cbl/Cblb/ mice also had an increased number
(up to 20%–40% more) of B1 B cells in the peritoneal
cavity than did the WT mice (Figure 1A and data not
shown). Based on these results, we conclude that the
Cbl/Cblb/ mutation alters the development of multi-
ple B cell subsets in the periphery.
Cbl/Cblb/ Mice Spontaneously Manifest
SLE-like Disease
Our inspection revealed that while the WT control mice
(10/10) remained normal beyond 10 months of age, 50%
(6/11) of Cbl/Cblb/ mice became moribund during
the same period. The mutant mice also possessed a sub-
stantially (3- to 5-fold) higher amount of serum IgM anti-
bodies as compared to WT, Cbl/, and Cblb/ mice;
however, the serum amounts of other Ig isotypes in the
mutant mice appeared to be similar to that in control
mice (Figure 2A). To determine whether immune tolerance
was impaired in the mutant mice, we first examined the
Immunity
Role of Cbl Ubiquitin Ligases in B Cell ToleranceFigure 1. Flow Cytometric and Statistic Analysis of B Cell Subsets in Cbl/Cblb/ Mice
(A) B cell subsets in bone marrow, spleen, lymph node, and peritoneal cavity. Pro- and pre- (B220lo IgM), immature (B220lo IgM+), and recirculating
mature B (B220hi IgM+) cells were gated as shown for analysis of B220 and IgM expression on bone-marrow cells. Percentages of bone-marrow cells
in those B cell subsets are indicated. Total splenic and lymph node cells were stained with anti-B220, anti-IgM, and anti-IgD. Percentage of B220+ B
cells that are IgDhi IgM+ and IgDlo IgMhi are indicated. Peritoneal cavity cells were stained with anti-CD5, anti-B220, and anti-IgM. Shown in the gates
are the percentage of peritoneal cavity cells in B1 (CD5lo B220lo) and B2 (CD5 B220hi) B cell subsets.
(B) Spenic B cell subsets. Splenic B cells were stained with anti-B220, anti-AA4.1, anti-CD24 (HSA), anti-CD21, and anti-CD23. Shown are AA4.1 and
HSA expression of the gated B220+ B cells (left), CD21 and CD23 expression on the gated B220+ AA4.1hi HSAhi immature B cells (middle), and B220+
AA4.1lo HSAlo mature B cells (right). Percentages of B cell subsets within the indicated gates are given. Phenotypes of T1, T2, MZ, B1, and FO B cells
are described in text.
(C) The numbers of total splenic B cells and B cell subsets. Data were collected from five 2-month-old WT and Cbl/Cblb/ mice.titers of serum autoantibodies of anti-double-stranded
DNA (anti-dsDNA) and presence of anti-nuclear antigen
(ANA) by ELISA and immunofluorescent staining, respec-
tively. We found that a high percentage of Cbl/Cblb/
mice but not WT littermates possessed anti-dsDNA and
ANA of both IgG (Figures 2B and 2C) and IgM (data not
shown) isotypes in the sera, suggesting that the mutant
mice developed autoimmune diseases. To directly assess
whetherCbl/Cblb/micemanifested autoimmune dis-
eases, we performed histopathological analysis on vari-
ous tissues from the mutant and control mice. Compared
to the WT or Cblb/ (data not shown) mice in which the
tissue infiltration of leukocytes were absent, we found
massive infiltrations of leukocytes in liver, lung, kidney,
and salivary grand of Cbl/Cblb/ mice that developed
the diseases (Figure 2D). Immunohistological analysis on
kidney sections of the mutant mice revealed greatly en-
larged glomeruli (average diameter, 76.02 ± 12.72 versus49.12 ± 8.28 mM [n = 40 glomeruli], p < 0.001) and severe
glomerular deposits of IgG and IgM antibodies when com-
pared to controls (Figure 2E). These results thus suggest
that the Cbl/Cblb/ mutant mice developed SLE-like
autoimmune disorders. Because our double-deficient
mice carried the Cbl/Cblb/ mutation only in B cells
and Cblb/ mice did not develop spontaneous autoim-
mune diseases (Chiang et al., 2000), we propose that
the simultaneous ablation of Cbl and Cbl-b in B cells dis-
rupts the B cell-intrinsic program for immune-tolerance
induction.
Cbl/Cblb/ B Cells Are Not Hyperactive
in Response to Antigen Stimulation
Impaired B cell tolerance is frequently associated with B
cell hyperactivity or resistance to apoptosis. To determine
whether the Cbl/Cblb/ mutation affected B cell
activation in vivo, we examined T-dependent (TD) andImmunity 26, 567–578, May 2007 ª2007 Elsevier Inc. 569
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Role of Cbl Ubiquitin Ligases in B Cell ToleranceFigure 2. Serum Antibody Titers and Pathological Analyses of Cbl/Cblb/ Mice
(A) Serumconcentrations of immunoglobulins (Ig) of different Ig isotypes. Datawere collected from 8- to 10-week-oldWT,Cbl/, Cblb/, andCbl/
Cblb/ mice. Each symbol represents the data from one individual mouse.
(B) Increased titers of dsDNA antibodies inCbl/Cblb/mice. Sera were obtained from 8- to 10-month-oldWT andCbl/Cblb/mice. Shown are
the titers of anti-dsDNA IgG in sera (1:1000 dilution) of WT and Cbl/Cblb/ mice.
(C) Serum anti-nuclear antibodies (ANA) ofCbl/Cblb/mice. Sera samples (1:100 dilution) fromCbl/Cblb/mice andWT littermates were used
for the ANA analysis. Shown are Hep2 cells stained with sera from WT and Cbl/Cblb/ mice. Bound IgG (green) was detected with FITC-conju-
gated anti-mouse IgG. Cells are counterstained with Evans blue (EB) to visualize cytoplasmic region (red).
(D) Perivascular infiltration of leukocytes in Cbl/Cblb/ mice. Liver, lung, kidney, and salivary gland sections from WT and Cbl/Cblb/ mice
were stained with haematoxylin and eosin (H&E).
(E) Glomerulonephritis and immunoglobulin deposits in kidney ofCbl/Cblb/mice. Kidney sections fromCbl/Cblb/ andWTmicewere stained
with H&E (top) or immunofluorescently stained with anti-mouse IgM (IgM) (middle) or anti-mouse IgG (IgG) (bottom). Shown are glomeruli with IgM
(green) or IgG (red) antibody deposits, respectively. Results are representative of 4 Cbl/Cblb/ and 4 WT mice.T-independent (TI) antibody responses in these mice. We
immunizedWT andCbl/Cblb/mice either with hapten
nitrophenyl-acetyl (NP)-conjugated keyhole limpet hemo-
cyanin (KLH) for TD antibody responses or with NP-Ficoll
or NP-lipopolysacharide (LPS) for type I or type II TI re-
sponses. In NP-KLH-immunized Cbl/Cblb/ mice,
the amounts of NP-specific IgM responses were compa-
rable to that produced by WT, Cbl/, and Cblb/
mice; however, the production of NP-specific IgG1 and
IgG2b in the mutant mice were moderately lower than
that in control mice (Figure 3A). Similarly, while Cbl/
Cblb/ mice had a comparable titer of anti-NP IgM to
that produced by WT, Cbl/, and Cblb/ mice after
NP-Ficoll immunization, they produced substantially
lower amounts of anti-NP IgG3 than did the control570 Immunity 26, 567–578, May 2007 ª2007 Elsevier Inc.mice (Figure 3B). The titers of NP-specific IgM and IgG3
in NP-LPS-immunized mutant and WT mice were
comparable (Figure 3C), indicating that the type II TI anti-
body response was not affected by the Cbl/Cblb/
mutation.
To determine whether theCbl/Cblb/mutation influ-
enced B cell activation and survival in vitro, we assessed
the proliferation and apoptosis of purified splenic B cells
upon anti-IgM stimulation. The proliferative response of
Cbl/Cblb/ B cells to anti-IgM stimulation alone was
severely impaired as compared to that ofWT B cells; how-
ever, the proliferation of themutant B cells was restored to
normal in the presence of IL-4 or anti-CD40 (Figure 3D).
The defective proliferation of mutant B cells in response
to anti-IgM stimulation was not likely caused by a different
Immunity
Role of Cbl Ubiquitin Ligases in B Cell ToleranceFigure 3. In Vivo and In Vitro B Cell Responses to Antigen Stimulation
(A) T-dependent antibody responses to NP-KLH in Cbl/Cblb/ mice. Sera were collected from WT, Cbl/, Cblb/, and Cbl/Cblb/ mice at
days 7 and 14 after immunization. Shown are the titers of NP-specific antibodies in different Ig isotypes. Antibody titers in day 7 WT immunized mice
are arbitrarily defined as 100 (relative unit).
(B and C) Type I and type II T-independent antibody responses. Sera were collected fromWT,Cbl/, Cblb/, andCbl/Cblb/mice at day 7 after
immunization with NP-Ficoll (B) or NP-LPS (C). Results in (A), (B), and (C) are representatives of at least three independent experiments, each con-
taining at least 5 mice of each genotypes.
(D) BCR-induced B cell proliferation. Purified splenic B cells were stimulated with anti-IgM alone, with anti-IgM together with anti-CD40 or IL-4, or with
anti-CD40 and IL-4. The rate of cell proliferation was determined based on [3H]thymidine incorporation.
(E) BCR-induced upregulation of cell-surface activation markers. Purified B cells fromWT and Cbl/Cblb/mice were stimulated with anti-IgM for
24 hr. The expression of cell-surface CD69, CD86, and I-Ab were determined by flow cytometry. Shadowed areas, nonstimulated B cells; solid lines,
anti-IgM-stimulated B cells.
(F) BCR-induced apoptosis ofCbl/Cblb/B cells. Purified B cells were stimulated with either anti-IgM alone or with anti-IgM plus anti-CD40 or IL-4
for 3 days. Cell death was determined by Annexin V staining. Shown are the percentages of Annexin V-positive cells.
(G) BAFF-dependent cell-survival assay. Purified splenic T1 and T2 (AA4.1hi HSAhi) and mature (AA4.1lo HSAlo) B cells from WT (open circles) and
Cbl/Cblb/ (solid dots) mice were cultured for 4 days in the presence or absence of 100 ng/ml BAFF. Apoptotic cells were analyzed by Annexin
V staining and propidium iodide (PI) double staining, and percentages of viable (Annexin V and PI) cells are plotted against time in days. Results are
representative of three independent experiments.ratio of immature versus mature B cells between WT and
Cbl/Cblb/ B cell compartment, because a similar de-
fect was also found in purified mature (B220+ AA4.1lo
HSAlo) B cells (Figure S2). It was unlikely a result of im-
paired B cell activation either, because the mutant B cells
upregulated cell-surfacemarkersCD69,CD86, andMHC II
as efficiently as did the WT B cells upon anti-IgM stimula-tion (Figure 3E). To determine whether the Cbl/Cblb/
mutation promoted BCR activation-induced cell death,
we analyzed apoptosis of Cbl/Cblb/ B cells after
BCR stimulation in the presence or absence of anti-CD40
or IL-4 (Figure 3F). Cbl/Cblb/ B cells exhibited a
much higher rate of apoptosis than did the WT cells upon
stimulation with IgM antibody alone; however, theImmunity 26, 567–578, May 2007 ª2007 Elsevier Inc. 571
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Role of Cbl Ubiquitin Ligases in B Cell ToleranceFigure 4. Impaired BCell Anergy to sHEL
Antigen in Cbl/Cblb/ Mice
(A) Cell-surface BCR expression on Cbl/
Cblb/ and WT B cells. Shown are histo-
grams of HEL-specific BCR (IgMa) expression
(top) and sHEL-binding activity (bottom) on
WT (IgHEL sHEL double transgenic) and Cbl/
Cblb/ (Cbl/Cblb/ IgHEL sHEL double
transgenic) B cells (solid lines). Shadowed
areas represent IgHEL Tg mice. The IgMa ex-
pression and sHEL-binding activity on WT B
cells are lower than that on Cbl/Cblb/ B
cells.
(B) Normal maturation of Cbl/Cblb/, IgHEL
B cells against HEL antigen. Total splenic cells
were stained with anti-B220, anti-AA4.1, and
anti-HSA. Shown are dot plot profiles of anti-
AA4.1 and anti-HSA staining of the gated B
cells from IgHEL sHEL double transgenic and
Cbl/Cblb/ IgHEL sHEL double transgenic
mice. The numbers indicate the percentage
of B220+ B cells that are mature (AA4.1lo
HSAlo).
(C) BCR-induced activation of IgHEL sHEL dou-
ble transgenic B cells. B cells from IgHEL trans-
genic and IgHEL sHEL double transgenic and
Cbl/Cblb/ IgHEL and Cbl/Cblb/ IgHEL
sHEL double transgenic mice were stimulated
with anti-IgM (Fab’)2. Shown at the top are his-
tograms of cell-surface CD86 expression on
stimulated (solid line) and unstimulated (shad-
owed area) B cells. Ca2+ mobilization was de-
termined by measuring the intracellular Ca2+
concentration [Ca2+]i by flow cytometry (bot-
tom). Results are representatives of at least
three independent experiments.difference of cell death between themutant andWTBcells
diminished substantially in the presence of anti-CD40 or
IL-4.
BAFF (B cell activation factor of the tumor necrosis fac-
tor family) signaling plays a critical role in B cell survival,
and enhanced BAFF signaling has been linked to B cell-
mediated autoimmune diseases (Lesley et al., 2004; Thien
et al., 2004). To test whether the Cbl/Cblb/ mutation
affected BAFF signaling, we cultured Cbl/Cblb/ and
WT B cells for 4 days in the presence or absence of
BAFF and then analyzed the rates of cell apoptosis by
flow cytometry. We found that the addition of BAFF res-
cued both mutant and WT B cells from apoptosis as com-
pared to the cultured cells without BAFF. In the immature
B cell compartment, WT B cells exhibited a slightly better
survival rate than did Cbl/Cblb/ B cells. These results
thus suggest that BAFF signaling is not enhanced in
Cbl/Cblb/ B cells (Figure 3G).
Taken together, we conclude thatCbl/Cblb/B cells
are neither hyperresponsive to BCR stimulation (in vivo or
in vitro), nor are they resistant to anti-IgM-induced apo-
ptosis or exhibiting an enhanced BAFF signaling. These
results also suggest that manifestation of the SLE-like dis-
ease in Cbl/Cblb/ mice is unlikely a consequence of
generalized B cell hyperactivation or improved survival
mediated by BAFF signals.572 Immunity 26, 567–578, May 2007 ª2007 Elsevier Inc.Impaired B Cell Anergy to Self-Antigen
in Cbl/Cblb/ Mice
Whereas B cell tolerance can be achieved through differ-
ent mechanisms such as clonal deletion, BCR editing, and
anergy of autoreactive B cells (Chen et al., 1995; Good-
now et al., 1988, 1995; Nemazee and Buerki, 1989), induc-
tion of anergy to self-antigen is a final safeguard to pre-
vent autoreactivity (Rajewsky, 1996). To determine
whether the Cbl/Cblb/ mutation affected B cell
anergy, we crossed Cbl/Cblb/ mice to BCR trans-
genic mice that expressed membrane IgM specifically
recognizing hen egg lysozyme (HEL) (IgHEL) and soluble
HEL (sHEL) transgenic mice. We found that approximately
50% (3/6) of Cbl/Cblb/ IgHEL sHEL mice became sick
and eventually died by 3 months of age. Further analyses
revealed that Cbl/Cblb/ IgHEL B cells in Cbl/
Cblb/ IgHEL sHEL mice were not anergic to the HEL an-
tigen, as shown by the fact that they showed a higher ex-
pression of IgMa (encoded by IgHEL transgene), exhibited
a higher sHEL binding activity, and entered the stage of
mature (AA4.1lo HSAlo) B cells (Figures 4A and 4B). Addi-
tionally, upon anti-IgM stimulation, the mutant B cells effi-
ciently upregulated CD86 and MHC II and elicited Ca2+ in-
flux albeit at an amount slightly lower than that in WT cells
(Figure 4C). On the contrary, the WT IgHEL B cells from
IgHEL sHEL double-transgenic mice exhibited typical
Immunity
Role of Cbl Ubiquitin Ligases in B Cell ToleranceFigure 5. Differential Dysregulation of BCR Downstream Signaling Pathways in Cbl/Cblb/ B Cells
Purified B cells were stimulated with anti-IgM F(ab’)2 for various periods of time as indicated. The amounts of tyrosine phospho-proteins in the cell
lysates were determined by immunoprecipitation and immunoblot analyses by an anti-phosphotyrosine. Protein loadings were quantified with the
corresponding antibodies.
(A) Tyrosine phosphorylation of total cellular proteins in Cbl/Cblb/ and WT B cells.
(B) Tyrosine phosphorylation of individual BCR downstream signaling components in Cbl/Cblb/ and WT B cells.
(C) BCR-induced Ca2+ mobilization in WT, Cbl/, Cblb/, and Cbl/Cblb/ B cells.phenotypes of anergic B cells, because they substantially
downmodulated cell-surface IgMa and HEL-binding ability
and failed to develop into follicular B cells (Figures 4A and
4B). Anti-IgM stimulation could not induce CD86 andMHC
II expression, nor did the Ca2+ response in these anergic B
cells (Figure 4C). Based on these data, we conclude that B
cell anergy is at least one of the major reasons that con-
tribute to the manifestation of the SLE-like autoimmune
disease in these mice.
Differential Alterations of BCR-Proximal Signaling
in Cbl/Cblb/ B Cells
The strength of BCR-proximal signaling plays a critical
role in peripheral B cell tolerance and activation (Monroe,
2004; Rajewsky, 1996). It may also dictate the develop-
ment and differentiation of immature B cells into follicular,
B1, and MZ B cells: it has been shown that strong BCR
signaling facilitates the development of MZ and B1 B cells
whereas weak BCR signaling favors the differentiation of
follicular B cells (Casola et al., 2004). The Cbl/Cblb/mutation altered the ratios of follicular B cells to B1 and
MZ B cells (Figure 1C), so we decided to assess whether
BCR-proximal signaling was enhanced in Cbl/Cblb/
B cells after anti-IgM stimulation. We found that stimula-
tion of Cbl/Cblb/ B cells elicited markedly enhanced
and prolonged tyrosine phosphorylation of total cellular
proteins as compared to that of WT B cells (Figure 5A).
In particular, the mutant B cells exhibited substantially
protracted higher amounts of tyrosine phosphorylation
of Ig-a, Syk, PLC-g2, and Vav, as well as Erk MAP kinase
activities, than did the control cells (Figure 5B). Addition-
ally, a prolonged and elevated amount of Ca2+ mobiliza-
tion was also found in Cbl/Cblb/ B cells as compared
to WT cells (Figure 5C). Surprisingly, tyrosine phosphory-
lation of BLNK was dramatically decreased in the mutant
B cells as compared to that in WT B cells (Figure 5B), indi-
cating that theCbl/Cblb/mutation exerted a differen-
tial effect on BCR-proximal signaling pathways. A strong
phosphorylated band of approximate 70–75 kDa was re-
producibly coimmunoprecipitated with BLNK, althoughImmunity 26, 567–578, May 2007 ª2007 Elsevier Inc. 573
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Taken together, we conclude that Cbl proteins differen-
tially control both the strength and duration of multiple
BCR-proximal signaling pathways. Additionally, since
most BCR-proximal signaling pathways are enhanced
whereas BLNK phosphorylation is attenuated in Cbl/
Cblb/ B cells, we propose that the loss of coordination
between these BCR-proximal signaling pathways is likely
responsible for the impaired B cell tolerance in Cbl/
Cblb/ mice.
Blockage of BCR Downmodulation and Ig-a
and Syk Ubiquitination in Cbl/Cblb/ B Cells
Cbl proteins negatively regulate TCR signaling by promot-
ing downmodulation of the TCR complex and ubiquitina-
tion of intracellular signaling components such as Lck
tyrosine kinase and phosphoinositide-3 kinase p85 sub-
unit (PI-3 kinase [p85]) (Fang and Liu, 2001; Naramura
et al., 2002; Rao et al., 2002b). The BCR delivers signals
in amanner similar to the TCR, so we investigated whether
the Cbl/Cblb/ mutation affected BCR downmodula-
tion and ubiquitination of BCR-downstream signaling
components. To determine whether BCR downmodula-
tion was blocked in the absence of Cbl proteins, we cross-
linked cell-surface IgM ofCbl/Cblb/mutant andWTB
cells with biotinylated anti-IgM (Fab’)2 for various periods
of time and then monitored the remaining cell-surface IgM
by staining the cells with fluorescent streptavidin (Fig-
ure 6A). In the absence of crosslinking, the mutant B cells
expressed a slightly higher amount of cell-surface IgM
than did the WT cells. Although BCR crosslinking for 5
min already resulted in a substantial loss of cell-surface
IgM on the WT B cells, the same treatment induced little
change with respect to the amount of cell-surface IgM
on the mutant B cells for at least 20 min, indicating that
Cbl proteins indeed play a critical role in BCR downmodu-
lation.
Cbl proteins form complexes with BCR-downstream
signaling components, including Ig-a, Syk, PLC-g2,
BLNK, PI-3 kinase (p85), and Vav. To explore whether
Cbl protein-mediated ubiquitination was involved in BCR
downmodulation and BCR signaling, we examined ubiqui-
tination of these signaling components in WT and Cbl/
Cblb/ B cells after anti-IgM stimulation. We found that
Ig-a and Syk were heavily ubiquitinated in WT but not
Cbl/Cblb/ B cells (Figure 6B). By contrast, we could
not detect any meaningful ubiquitination of PLC-g2,
BLNK, PI-3 kinase (p85), and Vav in either WT or Cbl/
Cblb/ B cells (data not shown). Interestingly, despite
their ubiquitinations, the amounts of Ig-a and Syk in WT
B cells did not seem to be affected even at 60 min after
the stimulation (Figure 6B and data not shown), suggest-
ing that Cbl proteins might regulate the signaling of these
molecules through a nondegradation mechanism.
Taken together, our results indicate that Cbl proteins
selectively promote ubiquitination of the BCR-down-
stream signaling components including Ig-a and Syk dur-
ing BCR activation. Ig-a is constitutively associated with
membrane IgM and its ubiquitination state is closely574 Immunity 26, 567–578, May 2007 ª2007 Elsevier Inc.Figure 6. Impaired BCR Downmodulation and Ubiquitination
in Cbl/Cblb/ B Cells
(A) BCR downmodulation. Shown are histograms of cell-surface IgM
expression on Cbl/Cblb/ and WT B cells after BCR crosslinking
for 5, 10, and 20 min.
(B) Ubiquitination of BCR-proximal signaling components. Cbl/
Cblb/ and WT B cells were stimulated with anti-IgM (Fab’)2 for
2 min. Ig-a and Syk in the cell lysates were immunoprecipitated and
immunoblotted to a membrane. The amounts of Ig-a and Syk ubiquiti-
nation were determined by an ubiquitin antibody.
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fore likely that Cbl proteins downmodulate the activated
BCR, hence the BCR signaling by promoting Ig-a ubiquiti-
nation.
DISCUSSION
In this study, we show that the simultaneous ablation of E3
ubiquitin ligases Cbl and Cbl-b in B cells results in mani-
festation of SLE-like autoimmune disease, as evidenced
by high production of serum autoantibodies against
dsDNA and ANA, as well as pathological alterations in kid-
ney and other major organs. Cbl/Cblb/ B cells were
not generally hyperresponsive to antigen stimulation in
terms of antibody production and proliferation. However,
BCR anergy to soluble protein antigen (sHEL) was im-
paired. Because in this mouse model the Cbl and Cbl-b
are simultaneously inactivated only in B cells, we conclude
that Cbl proteins control B cell-intrinsic checkpoint of
tolerance induction.
B cell-mediated autoimmunity is frequently linked to the
hyperactivation of B cells. In this regard, mice deficient in
tyrosine kinase Lyn, tyrosine phosphatase SHP-1, or
membrane receptor CD22 exhibit B cell hyperresponsive-
ness upon BCR stimulation and manifest systemic auto-
immune diseases (Cyster and Goodnow, 1995; Hibbs
et al., 1995; O’Keefe et al., 1996). In addition to this mech-
anism, mutations that influence B cell apoptosis and sur-
vival may also affect immune tolerance, because the
germline deletion of protein kinase C-d (PKC-d) or over-
production of BAFF in mice, both of which promote the
survival of B cells, cause severe autoimmune diseases
(Lesley et al., 2004; Saijo et al., 2003; Thien et al., 2004).
In contrast to these two mechanisms, we found that
Cbl/Cblb/ B cells were not hyperactive to antigen
stimulation either in vitro or in vivo. They were not resistant
to BCR-induced apoptosis, nor did they exhibit any en-
hancement in BAFF signaling. These findings therefore
suggest that Cbl proteins control B cell tolerance through
a different mechanism. It is generally believed that B cell
tolerance may occur at immature B cell stage. In contrast
to mature B cells that are activated when encountering an
antigen, immature B cells usually become tolerized upon
BCR triggering (Allman et al., 2001; Carsetti et al., 1995;
Loder et al., 1999; Monroe, 2004; Rajewsky, 1996). Under
physiological condition, immature B cells may take 3–4
days to become immune-competent mature B cells (All-
man et al., 1993; Rolink et al., 1998). This period of B
cell maturation naturally constitutes a time window when
autoreactive B cells can be checked by various tolerance
mechanisms such as clonal deletion, BCR editing, and
anergy (Chen et al., 1995; Goodnow et al., 1995; Nemazee
and Buerki, 1989). Our preliminary data suggest that the
Cbl/Cblb/ mutation may expedite B cell maturation
(data not shown). We therefore propose that this alteration
could dramatically shorten the susceptible period of im-
mune tolerance against autoreactive B cells, conse-
quently breaking down the immune tolerance. This hypo-
thetic model of B cell tolerance is also supported bya recent observation that administration of female hor-
mone prolactin may concomitantly facilitate B cell matura-
tion and development of SLE-like disease in anti-DNA an-
tibody transgenic mice (Peeva et al., 2003). Our results
revealed that B cell anergy to soluble HEL antigen was im-
paired in Cbl/Cblb/ mice, so more experiments are
needed to assess whether a shortened duration of B cell
maturation is directly responsible for the impaired B cell
anergy to autoantigen in Cbl/Cblb/ mice. It should
be noted that we also found that while the mutant B cells
still underwent BCR editing, the efficiency of the second-
ary rearrangement of the k chains in the absence of Cbl
proteins seemed to be less efficient (data not shown). It
is therefore necessary to further investigate whether
BCR editing is partially impaired by Cbl/Cblb/ muta-
tion. Finally, we found thatCbl/Cblb/mice possessed
more B1 B cells, and it remains to be determined whether
the observed autoimmune symptom is linked to the abnor-
mal development and function of B1 B cells.
Molecular mechanisms by which Cbl proteins regulate
BCR signaling remain unclear. Previous experiments
show that both Cbl and Cbl-b may function as E3 ubiquitin
ligases in T cells (Joazeiro et al., 1999). Cbl and Cbl-b di-
rectly or indirectly form complexes with the Ig-a, Syk,
PLC-g2, PI-3 kinase (p85), Vav, and BLNK (Bachmaier
et al., 2000; Fang and Liu, 2001; Rao et al., 2002a; Sohn
et al., 2003; and data not shown). However, we noted
that in B cells, the Cbl/Cblb/ mutation abolished
BCR-induced Ig-a and Syk ubiquitination but did not af-
fect the ubiquitination states of PI-3 kinase, PLC-g2,
Vav, and BLNK, despite the fact that tyrosine phosphory-
lation of these molecules was markedly altered. Ig-a and
Syk function at the top of the BCR-signaling cascade, so
our results thus support the idea that Cbl proteins may
negatively regulate BCR-signaling cascade at the top of
BCR-induced tyrosine phosphorylation cascade by pro-
moting Ig-a and Syk ubiquitination. We could not detect
any meaningful degradation of Ig-a and Syk even after 1
hr of BCR stimulation, so we believe that the ubiquitination
of Ig-a and Syk by Cbl proteins might not direct them for
degradation, but rather alter their transportation and/or
association with other molecules during BCR signaling.
A similar observation that PI-3 kinase (p85) is ubiquitinated
but not degraded by Cbl-b has been reported in T cells
(Fang and Liu, 2001). This conclusion of course cannot ex-
clude the possibility that only a small fraction of Ig-a and
Syk are ubiquitinated by Cbl proteins so that the degrada-
tion of these molecules is below the detectable level in our
assay system.
It should be mentioned that T cells in our Cbl/Cblb/
mice were deficient in Cbl-b. Because our Cblb/ mice
are susceptible to autoimmune diseases (Chiang et al.,
2000), it is possible that in Cbl/Cblb/ mice, the
Cblb/ T cells also contribute to the development of
SLE-like disease. However, becausewe did not find a sim-
ilar autoimmune symptom in the littermate Cblb/ (Cblf/f
Cblb/) mice, we believe that B cell-intrinsic ablation of
Cbl and Cbl-b are necessary for the development of the
SLE-like diseases in our animal model. In support of thisImmunity 26, 567–578, May 2007 ª2007 Elsevier Inc. 575
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deed exhibited B cell-intrinsic alterations in terms of mat-
uration and BCR signaling. Additionally, anergy of IgHEL B
cells to sHEL was abolished, indicating that a B cell-intrin-
sic defect has developed in the absence of Cbl proteins.
Further experiments will be helpful to assess to what ex-
tent B cell-intrinsic Cbl/Cblb/ mutation affects B cell
tolerance induction and whether Cbl/Cblb/ B cells
are sufficient for the manifestation of the SLE-like dis-
eases in the absence of T cell help.
EXPERIMENTAL PROCEDURES
Mice
Cbl-floxed, Cblb-deficient, and Cd19-Cre transgenic mice were de-
scribed previously (Naramura et al., 2002). To generate Cbl/Cblb/
mice, Cbl-floxed mice were crossed to Cblb
/
mice and then to
Cd19-Cre transgenic mice kindly provided by A. Tarakhovsky and
K. Rajewsky (Rickert et al., 1997). Mice used in this study were of
a mixed C57BL/6 and 129 background. IgHEL and sHEL transgenic
mice were originally generated by Goodnow et al. (1988) and were
kindly provided by A. Tarakhovsky. All mice used in this study were
maintained and used at The Twinbrook II Facility of NIAID and the
Columbia University Hammer Health Science Center mouse facility
under specific pathogen-free conditions according to institutional
guidelines and animal study proposals approved by the institutional
animal care and use committees.
Antibodies and Reagents
CD5, CD21, CD23, CD24 (HSA), B220, IgM, IgD, CD69, CD86, I-Ab,
and AA4.1 antibodies were fromBD PharMingen. The purified and bio-
tinylated goat anti-mouse IgMF(ab’)2 antibody used for BCR crosslink-
ing was from Jackson Immunoresearch Laboratory. Ig-a antibody was
from S.K. Pierce. Anti-BLNK was obtained from A. Chan and D. Kita-
mura. Anti-Syk, PLC-g2, Vav, ubiquitin, phospho-ERK, and ERK1/2
were from Santa Cruz Biotechnology, Inc. Anti-phosphotyrosine
(4G10) was from Upstate. BAFF was from Apotech Biochemicals.
Anti-CD40 and IL-4 were from BD PharMingen.
T-Dependent and T-Independent Antibody Responses
and ELISA
6- to 10-week-old mice were immunized i.p. with 50 mg of NP-KLH for
TD immune response, NP-Ficoll for type I TI immune response, or
NP-LPS for type II TI immune response. The antigens were precipi-
tated in 100 ml of Imject-Alum adjuvant (Pierce). Immunized mice
were bled from the tail vein on day 7 and 14 after primary immunization.
The titers of NP-specific antibodies of different Ig isotypes were deter-
mined by ELISA as described previously (Chiang et al., 2000).
In Vitro B Cell Proliferation and Apoptosis Assays
B cells were purified with MACS column according to a B cell enrich-
ment protocol (Miltanyi Biotek) and were more than 95% pure based
on cell-surface CD19 staining. FACS purification of T1 and T2
(AA4.1hi HSAhi) and follicular (AA4.1lo HSAlo CD21hi CD23hi) B cells
was performed after staining cells with anti-AA4.1, HSA, CD23, and
CD21. Purified B cells (1 3 105 cells/well) were stimulated with 10
mg/ml anti-IgM F(ab’)2 or 10 mg/ml of LPS for 2 days in a 96-well plate.
For the anti-CD40 and IL-4 culture, 50 mg/ml anti-CD40 or 20 U/ml IL-4
were included in the culture. To determine the rates of cell proliferation,
cultured cells were pulsed with [3H]thymidine for 16 hr. Cells were then
harvested on a cell harvester and [3H]thymidine incorporation was
measured on a b-counter. To determine the dependence of cell sur-
vival on BAFF, purified immature or mature B cells were cultured for
up to 4 days in the presence of recombinant BAFF (100 ng/ml). Apo-
ptotic cells were quantified by staining the cells with FITC-conjugated576 Immunity 26, 567–578, May 2007 ª2007 Elsevier Inc.Annexin V and propidium iodide (PI). Upregulation of cell-surface
CD69, CD86, and I-Ab was determined by flow cytometry.
Ca2+ Mobilization
Freshly purified splenic B cells were loaded with Fura-red and Fluo-4
(Molecular Probe) in HBSS buffer containing 1% FBS at 37C for 30
min. After washing once with HBSS buffer, cells were stimulated
with 5 mg/ml anti-IgM (Fab’)2 fragment. Increase of intracellular Ca
2+
concentration in B220+ B cells was recorded in real time by flow
cytometry for 300 s.
BCR Downmodulation
Purified B cells were stained with biotinylated anti-IgM (Fab’)2 at 4C
for 15 min. After washing with PBS, cells were incubated at 37C pre-
warmed HBSS buffer containing 1% FBS to allow internalization of
BCR-anti-IgM (Fab’)2 complexes to occur. After various periods of in-
cubation, cells were immediately transferred into cold HBSS buffer
containing 0.1% sodium azide to stop further internalization. Cell-
surface-remaining anti-IgM (Fab’)2 were stained with streptavidin-PE
and quantified on an LSR II.
Immunoprecipitation and Immunoblot Analyses
Immunoprecipitation and immunoblot analyses were performed as
previously described (Naramura et al., 2002). In brief, purified B cells
were stimulated with anti-IgM (Fab’)2 for various periods and lysed in
RIPA buffer containing a mixture of proteinase and phosphatase inhib-
itors (0.1 mg/ml Aprotinin, 0.01 mg/ml Leupeptin, 0.2 mM PMSF, 1 mM
NaF, and 1 mM NaVO4). Ig-a, Syk, BLNK, Vav, and PLC-g2 in the cell
lysates were immunoprecipitated with the corresponding antibodies
and subjected to electrophoresis and immunoblotting. The amounts
of tyrosine phosphorylation and protein ubiquitination were deter-
mined with anti-phosphotyrosine and anti-ubiquitin, respectively
(Santa Cruz Biotechnology).
Histochemical and Immunofluorescent Staining
Mouse tissues were harvested, snap frozen in liquid nitrogen, and em-
bedded in OCT-embedding medium (Sakura Finetek). 8 mM sections
were air-dried and fixed with acetone. H&E staining was performed ac-
cording to a standard protocol (Miyamoto et al., 2002). Immunofluores-
cent staining was performed with the following reagents: anti-IgM-
FITC, anti-IgG-biotin (BD Biosciences), and streptavidin-Alexa 568
(Molecular Probes). Anti-nuclear antibodies (ANA) were detected by in-
tracellular staining of Hep2 cells with mouse serum (1:100 dilution), fol-
lowed by FITC-conjugated anti-mouse IgG. Evans Blue staining was
used to visualize cytoplasm.
Supplemental Data
Two figures are available at http://www.immunity.com/cgi/content/
full/26/5/567/DC1/.
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